Phase 3 Study of Roflumilast Cream 0.3% Shows Promise for Plaque Psoriasis
A Phase 3 study is underway to assess the efficacy and safety of roflumilast cream 0.3% in patients with plaque psoriasis.
Company
Pharmaceutical intelligence for Hangzhou Zhongmei Huadong Pharmaceutical with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.